Falling drug prices and high inventory in the United States present new
hurdles for Indian manufacturers.
By Keerthi Ramesh
India’s pharmaceutical sector reached a historic milestone this fiscal year with
exports climbing to a record $31.1 billion. While the figure marks a significant
achievement for the “pharmacy of the world” a closer look at the American market
reveals a shifting landscape of pricing pressures and stockpiled supplies that are
forcing Indian drugmakers to rethink their long-term strategies.
A report by the Economic Times highlights that the United States remains the
primary destination for Indian medicines, accounting for roughly 34% of all
outbound shipments. However, the closing months of the fiscal year signaled a
cooling period in the West.
Industry experts point to a massive inventory buildup within U.S. distribution
channels, largely driven by aggressive purchasing in late 2025 as buyers moved to get
ahead of shifting trade tariffs on patented drugs. As warehouses reached capacity, the
immediate demand for new shipments slowed, resulting in a sharp 10% dip in
exports to the U.S. in March.
Beyond the logistics of full warehouses, Indian manufacturers are grappling with a
“race to the bottom” regarding generic drug pricing. In American pharmacies, the
cost of standard generics has continued to slide, squeezing the profit margins of the
companies producing them.
Read more: Trump announces new tariffs on US pharmaceutical imports
Pharmaceuticals (September 26, 2025)
For the workers in manufacturing hubs like Hyderabad and Ahmedabad, this means
the era of relying solely on high volume, low cost “copycat” drugs is evolving. The
volatility of the U.S. market has underscored the need for a more resilient supply
chain that isn’t overly dependent on a single Western partner.
“The U.S. inventory buildup due to tariffs is the primary reason for this slowdown”
said Namit Joshi, chairman of the Pharmaceuticals Export Promotion Council of
India (Pharmexcil), in an interview with ET. He noted that while the inventory issues
may be temporary as stockpiles are depleted, the structural shift in the market
toward lower margins for generics is a permanent reality that requires a pivot in
business models.
READ: Pharmaceutical giant Eli Lilly to invest over $6 billion in Houston
Mergers & Acquisitions (September 24, 2025)
To counter the U.S. slowdown, Indian firms are aggressively diversifying their reach.
While shipments to the North American region faced headwinds, with NAFTA region
exports falling 7.9%, India saw double digit growth in emerging markets. Exports to
Africa surged by 13%, while Oceania rose 11.5%, and Latin America saw a 10%
increase. There is also a concerted effort to move up the value chain into more
complex medical fields. Instead of just producing basic tablets, companies are
finding success in vaccines, which grew by 26.4% to reach $1.5 billion this year.
For the American consumer, the continued presence of Indian pharma remains vital
for keeping healthcare costs manageable. However, the record $31.1 billion figure
serves as both a celebration of past success and a quiet warning. The future of the
industry likely rests not in doing the same things cheaper, but in the ability of Indian
scientists and manufacturers to innovate and find new homes for their life-saving
products beyond traditional Western borders.
Also read: Trump to implement tariffs on semiconductors, pharmaceuticals and auto
Politics (February 19, 2025)